Evidence map›Paper›PMID 26245929›Full record

ArticleNeurology2015

Risk factors for poor visual outcome in patients with idiopathic intracranial hypertension.

Michael Wall, Julie Falardeau, William A Fletcher, Robert J Granadier, Byron L Lam, Reid A Longmuir, Anil D Patel, Beau B Bruce, Hua He, Michael P McDermott and 1 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
4.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it, 88 citations in OpenAlex.

  1. Guideline
  2. Trial
  3. Review
  4. Prediction of Poor Visual Outcomes at Idiopathic Intracranial Hypertension Diagnosis Using a Supervised Machine Learning Algorithm.Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. The role of acetazolamide in critical care and emergency medicine.Journal of geriatric cardiology : JGC · 2024
    Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Michael WallFrom the Departments of Neurology and Ophthalmology (M.W.) and Ophthalmology and Visual Sciences (R.A.L.), University of Iowa, Iowa City; Casey Eye Institute (J.F.), Department of Ophthalmology, Oregon Health and Science University, Portland; Department of Clinical Neurosciences (W.A.F.), University of Calgary, Canada; William Beaumont Hospital (R.J.G.), Royal Oak, MI; Bascom Palmer Eye Institute (B.L.L.), University of Miami, FL; Dean A. McGee Eye Institute (A.D.P.), Oklahoma University, College of Medicine, Oklahoma City; Departments of Ophthalmology, Neurology, and Epidemiology (B.B.B.), Emory University, Atlanta, GA; and Department of Biostatistics and Computational Biology (H.H., M.P.M.), University of Rochester, NY. michael-wall@uiowa.edu.
Julie FalardeauFrom the Departments of Neurology and Ophthalmology (M.W.) and Ophthalmology and Visual Sciences (R.A.L.), University of Iowa, Iowa City; Casey Eye Institute (J.F.), Department of Ophthalmology, Oregon Health and Science University, Portland; Department of Clinical Neurosciences (W.A.F.), University of Calgary, Canada; William Beaumont Hospital (R.J.G.), Royal Oak, MI; Bascom Palmer Eye Institute (B.L.L.), University of Miami, FL; Dean A. McGee Eye Institute (A.D.P.), Oklahoma University, College of Medicine, Oklahoma City; Departments of Ophthalmology, Neurology, and Epidemiology (B.B.B.), Emory University, Atlanta, GA; and Department of Biostatistics and Computational Biology (H.H., M.P.M.), University of Rochester, NY.
William A FletcherFrom the Departments of Neurology and Ophthalmology (M.W.) and Ophthalmology and Visual Sciences (R.A.L.), University of Iowa, Iowa City; Casey Eye Institute (J.F.), Department of Ophthalmology, Oregon Health and Science University, Portland; Department of Clinical Neurosciences (W.A.F.), University of Calgary, Canada; William Beaumont Hospital (R.J.G.), Royal Oak, MI; Bascom Palmer Eye Institute (B.L.L.), University of Miami, FL; Dean A. McGee Eye Institute (A.D.P.), Oklahoma University, College of Medicine, Oklahoma City; Departments of Ophthalmology, Neurology, and Epidemiology (B.B.B.), Emory University, Atlanta, GA; and Department of Biostatistics and Computational Biology (H.H., M.P.M.), University of Rochester, NY.
Robert J GranadierFrom the Departments of Neurology and Ophthalmology (M.W.) and Ophthalmology and Visual Sciences (R.A.L.), University of Iowa, Iowa City; Casey Eye Institute (J.F.), Department of Ophthalmology, Oregon Health and Science University, Portland; Department of Clinical Neurosciences (W.A.F.), University of Calgary, Canada; William Beaumont Hospital (R.J.G.), Royal Oak, MI; Bascom Palmer Eye Institute (B.L.L.), University of Miami, FL; Dean A. McGee Eye Institute (A.D.P.), Oklahoma University, College of Medicine, Oklahoma City; Departments of Ophthalmology, Neurology, and Epidemiology (B.B.B.), Emory University, Atlanta, GA; and Department of Biostatistics and Computational Biology (H.H., M.P.M.), University of Rochester, NY.
Byron L LamFrom the Departments of Neurology and Ophthalmology (M.W.) and Ophthalmology and Visual Sciences (R.A.L.), University of Iowa, Iowa City; Casey Eye Institute (J.F.), Department of Ophthalmology, Oregon Health and Science University, Portland; Department of Clinical Neurosciences (W.A.F.), University of Calgary, Canada; William Beaumont Hospital (R.J.G.), Royal Oak, MI; Bascom Palmer Eye Institute (B.L.L.), University of Miami, FL; Dean A. McGee Eye Institute (A.D.P.), Oklahoma University, College of Medicine, Oklahoma City; Departments of Ophthalmology, Neurology, and Epidemiology (B.B.B.), Emory University, Atlanta, GA; and Department of Biostatistics and Computational Biology (H.H., M.P.M.), University of Rochester, NY.
Reid A LongmuirFrom the Departments of Neurology and Ophthalmology (M.W.) and Ophthalmology and Visual Sciences (R.A.L.), University of Iowa, Iowa City; Casey Eye Institute (J.F.), Department of Ophthalmology, Oregon Health and Science University, Portland; Department of Clinical Neurosciences (W.A.F.), University of Calgary, Canada; William Beaumont Hospital (R.J.G.), Royal Oak, MI; Bascom Palmer Eye Institute (B.L.L.), University of Miami, FL; Dean A. McGee Eye Institute (A.D.P.), Oklahoma University, College of Medicine, Oklahoma City; Departments of Ophthalmology, Neurology, and Epidemiology (B.B.B.), Emory University, Atlanta, GA; and Department of Biostatistics and Computational Biology (H.H., M.P.M.), University of Rochester, NY.
Anil D PatelFrom the Departments of Neurology and Ophthalmology (M.W.) and Ophthalmology and Visual Sciences (R.A.L.), University of Iowa, Iowa City; Casey Eye Institute (J.F.), Department of Ophthalmology, Oregon Health and Science University, Portland; Department of Clinical Neurosciences (W.A.F.), University of Calgary, Canada; William Beaumont Hospital (R.J.G.), Royal Oak, MI; Bascom Palmer Eye Institute (B.L.L.), University of Miami, FL; Dean A. McGee Eye Institute (A.D.P.), Oklahoma University, College of Medicine, Oklahoma City; Departments of Ophthalmology, Neurology, and Epidemiology (B.B.B.), Emory University, Atlanta, GA; and Department of Biostatistics and Computational Biology (H.H., M.P.M.), University of Rochester, NY.
Beau B BruceFrom the Departments of Neurology and Ophthalmology (M.W.) and Ophthalmology and Visual Sciences (R.A.L.), University of Iowa, Iowa City; Casey Eye Institute (J.F.), Department of Ophthalmology, Oregon Health and Science University, Portland; Department of Clinical Neurosciences (W.A.F.), University of Calgary, Canada; William Beaumont Hospital (R.J.G.), Royal Oak, MI; Bascom Palmer Eye Institute (B.L.L.), University of Miami, FL; Dean A. McGee Eye Institute (A.D.P.), Oklahoma University, College of Medicine, Oklahoma City; Departments of Ophthalmology, Neurology, and Epidemiology (B.B.B.), Emory University, Atlanta, GA; and Department of Biostatistics and Computational Biology (H.H., M.P.M.), University of Rochester, NY.
Hua HeFrom the Departments of Neurology and Ophthalmology (M.W.) and Ophthalmology and Visual Sciences (R.A.L.), University of Iowa, Iowa City; Casey Eye Institute (J.F.), Department of Ophthalmology, Oregon Health and Science University, Portland; Department of Clinical Neurosciences (W.A.F.), University of Calgary, Canada; William Beaumont Hospital (R.J.G.), Royal Oak, MI; Bascom Palmer Eye Institute (B.L.L.), University of Miami, FL; Dean A. McGee Eye Institute (A.D.P.), Oklahoma University, College of Medicine, Oklahoma City; Departments of Ophthalmology, Neurology, and Epidemiology (B.B.B.), Emory University, Atlanta, GA; and Department of Biostatistics and Computational Biology (H.H., M.P.M.), University of Rochester, NY.
Michael P McDermottFrom the Departments of Neurology and Ophthalmology (M.W.) and Ophthalmology and Visual Sciences (R.A.L.), University of Iowa, Iowa City; Casey Eye Institute (J.F.), Department of Ophthalmology, Oregon Health and Science University, Portland; Department of Clinical Neurosciences (W.A.F.), University of Calgary, Canada; William Beaumont Hospital (R.J.G.), Royal Oak, MI; Bascom Palmer Eye Institute (B.L.L.), University of Miami, FL; Dean A. McGee Eye Institute (A.D.P.), Oklahoma University, College of Medicine, Oklahoma City; Departments of Ophthalmology, Neurology, and Epidemiology (B.B.B.), Emory University, Atlanta, GA; and Department of Biostatistics and Computational Biology (H.H., M.P.M.), University of Rochester, NY.
NORDIC Idiopathic Intracranial Hypertension Study Group
University of Iowa · USUniversity of Miami · US

Funding

Neuro-Ophthalmology Research Disease Investigator Consortium (NORDIC) NetworkU10EY017281 · NEI · ST. LUKE'S-ROOSEVELT INST FOR HLTH SCIS · PI KUPERSMITH, MARK J · 2009 to 2014
$10.2M
Data Coordination and Biostatistics Center for the NORDIC NetworkU10EY017387 · NEI · UNIVERSITY OF ROCHESTER · PI KIEBURTZ, KARL D. · 2009 to 2013
$7.0M
Ocular fundus photos in the emergency room: a new application for telemedicine?K23EY019341 · NEI · EMORY UNIVERSITY · PI BRUCE, BEAU BENJAMIN · 2010 to 2014
$718k
NEI NIH HHS 1U10EY017281-01A1NEI NIH HHS 1U10EY017387-01A1NEI NIH HHS 1U10EY017387-01A1S1NEI NIH HHS 3U10EY017281-01A1S1NEI NIH HHS 3U10EY017281-01A1S2NEI NIH HHS K23EY019341NEI NIH HHS U10 EY017281
6 · The paper itself

Abstract

objectivesDetermine potential risk factors for progressive visual field loss in the Idiopathic Intracranial Hypertension Treatment Trial, a randomized placebo-controlled trial of acetazolamide in patients with idiopathic intracranial hypertension and mild visual loss concurrently receiving a low sodium, weight reduction diet.

methodsLogistic regression and classification tree analyses were used to evaluate potential risk factors for protocol-defined treatment failure (>2 dB perimetric mean deviation [PMD] change in patients with baseline PMD -2 to -3.5 dB or >3 dB PMD change with baseline PMD -3.5 to -7 dB).

resultsSeven participants (6 on diet plus placebo) met criteria for treatment failure. The odds ratio for patients with grades III to V papilledema vs those with grades I and II was 8.66 (95% confidence interval [CI] 1.65-∞, p = 0.025). A 1-unit decrease in the number of letters correct on the ETDRS (Early Treatment Diabetic Retinopathy Study) chart at baseline was associated with an increase in the odds of treatment failure by a factor of 1.16 (95% CI 1.04-1.30, p = 0.005). Compared with female participants, the odds ratio for male participants was 26.21 (95% CI 1.61-433.00, p = 0.02). The odds of treatment failure were 10.59 times higher (95% CI 1.63-116.83, p = 0.010) for patients with >30 transient visual obscurations per month vs those with ≤30 per month.

conclusionsMale patients, those with high-grade papilledema, and those with decreased visual acuity at baseline were more likely to experience treatment failure. All but one of these patients were treated with diet alone. These patients should be monitored closely and be considered for aggressive treatment of their idiopathic intracranial hypertension.

Indexed as

AcetazolamideAdultDiet, ReducingDiet, Sodium-RestrictedDiureticsFemaleHumansIntracranial HypertensionMalePapilledemaPrognosisRandomized Controlled Trials as TopicRisk FactorsSeverity of Illness IndexSex FactorsTreatment FailureAcetazolamideDiuretics

Identifiers

PMID26245929
PMCPMC4553022
OpenAlexW2159967001

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.